Background The interest on the role of Denosumab in the treatment strategy of giant cell
tumor of the spine is growing. En bloc resection is considered the Enneking appropriate …

Background Most patients with advanced prostate cancer develop bone metastases, which
often result in painful and debilitating skeletal-related events. Inhibitors of bone resorption …

Background We determined whether serum levels of Receptor Activator for Nuclear Factor κ
B Ligand (RANKL), Osteoprotegerin (OPG), and the RANKL/OPG ratio could be useful …

Osteolytic bone resorption is the primary cause of pain and suffering (eg pathological bone
fracture) in women with metastatic breast cancer. The current standard of care for patients …

PURPOSE Denosumab is used to treat patients with bone metastasis from solid tumors, but
sometimes causes severe hypocalcemia, so careful clinical management is important. This …

Denosumab is a fully human monoclonal antibody that binds to the receptor activator of
nuclear factor kappa-Β ligand, an essential cytokine factor in bone resorption, which reduces …

Denosumab is a fully human monoclonal antibody that binds to the receptor activator of
nuclear factor kappa-Β ligand, an essential cytokine factor in bone resorption, which reduces …

O presente relatório descreve o trabalho desenvolvido ao longo da unidade curricular de
Estágio para finalização do Mestrado Integrado em Ciências Farmacêuticas, tendo este sido …

This chapter serves as a review of publications in 2017 pertaining to new or unique adverse
drug events associated with cytokines and monoclonal antibodies. Case reports and large …

Background: Giant cell tumours (GCT) of the spine may be large at presentation and cause
severe pain. The current recommended treatment is en bloc excision but it is associated with …